This single-dose, single-site study will analyze the effects of ABT-538 on viral load at all stages of HIV-1 infection. It will also evaluate in detail the quantitative and qualitative CD4 response to ABT-538 therapy. From 6 - 12 patients will receive ABT-538 at 300 mg orally q.i.d., the highest dose level proven safe and effective another of our ongoing studies using this drug.
Showing the most recent 10 out of 470 publications